Logo

CytRx Drops Support for Blizzard, Psynomics

Jan 19, 2004

NEW YORK, Jan. 18 (GenomeWeb News) --  CytRx will stop supporting genomics companies Blizzard Genomics and Psynomics and write off its prior investments as losses, the company said on Friday.

 

CytRx, based in Los Angeles, said there is "substantial doubt about their abilities to continue as going concerns." As a result, the CytRx plans to write off its investments in Blizzard and Psynomics in the last quarter of 2003.

 

GGC Pharmaceuticals, which merged with CytRx in 2002, had invested about $1.65 million in cash in Blizzard and Psynomics. Since the merger, CytRx has invested less than $25,000 in the companies. The carrying value of these companies, as of Sept. 30, was about $5.85 million.

 

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.